ARABI, Y. M., FOWLER, R. & HAYDEN, F. G. 2020. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive care medicine, 46, 315-328.
BARON, S. A., DEVAUX, C., COLSON, P., RAOULT, D. & ROLAIN, J.-M. 2020. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19. Int J Antimicrob Agents, 105944.
BOOPATHI, S., POMA, A. B. & KOLANDAIVEL, P. 2020. Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment. Journal of Biomolecular Structure and Dynamics, 1-14.
BOSCH, B. J., VAN DER ZEE, R., DE HAAN, C. A. & ROTTIER, P. J. 2003. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. Journal of virology, 77, 8801-8811.
CHEN, N., ZHOU, M., DONG, X., QU, J., GONG, F., HAN, Y., QIU, Y., WANG, J., LIU, Y. & WEI, Y. 2020a. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395, 507-513.
CHEN, Y., GUO, Y., PAN, Y. & ZHAO, Z. J. 2020b. Structure analysis of the receptor binding of 2019-nCoV. Biochemical and biophysical research communications, 525, 135-140.
CHEN, Y., LIU, Q. & GUO, D. 2020c. Emerging coronaviruses: genome structure, replication, and pathogenesis. Journal of medical virology, 92, 418-423.
CHEN, Y. W., YIU, C.-P. B. & WONG, K.-Y. 2020d. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research, 9.
DE WIT, E., FELDMANN, F., CRONIN, J., JORDAN, R., OKUMURA, A., THOMAS, T., SCOTT, D., CIHLAR, T. & FELDMANN, H. 2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences, 117, 6771-6776.
EFFERTH, T. & KOCH, E. 2011. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Current drug targets, 12, 122-132.
ELFIKY, A. A., MAHDY, S. M. & ELSHEMEY, W. M. 2017. Quantitative structure‐activity relationship and molecular docking revealed a potency of anti‐hepatitis C virus drugs against human corona viruses. Journal of medical virology, 89, 1040-1047.
GAO, Y., YAN, L., HUANG, Y., LIU, F., ZHAO, Y., CAO, L., WANG, T., SUN, Q., MING, Z. & ZHANG, L. 2020. Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target. BioRxiv.
GE, X.-Y., LI, J.-L., YANG, X.-L., CHMURA, A. A., ZHU, G., EPSTEIN, J. H., MAZET, J. K., HU, B., ZHANG, W. & PENG, C. 2013. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature, 503, 535-538.
HASAN, A., PARAY, B. A., HUSSAIN, A., QADIR, F. A., ATTAR, F., AZIZ, F. M., SHARIFI, M., DERAKHSHANKHAH, H., RASTI, B. & MEHRABI, M. 2020. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin. Journal of Biomolecular Structure and Dynamics, 1-13.
HOFFMANN, M., KLEINE-WEBER, H., SCHROEDER, S., KRÜGER, N., HERRLER, T., ERICHSEN, S., SCHIERGENS, T. S., HERRLER, G., WU, N.-H. & NITSCHE, A. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell.
HOFMANN, H. & PÖHLMANN, S. 2004. Cellular entry of the SARS coronavirus. Trends in microbiology, 12, 466-472.
HUI, D., AZHAR EI, MADANI TA, NTOUMI F, KOCK R, DAR O, IPPOLITO G, MCHUGH TD, MEMISH ZA, DROSTEN C, ZUMLA A & E, P. 2020. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-the latest 2019 novel coronavirus outbreak in Wuhan. China, 91, 264-266.
HUMPHREY, W., DALKE, A. & SCHULTEN, K. 1996. VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14, 33-38.
KAI, H. & KAI, M. 2020. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertension Research, 1-7.
KONG, R., YANG, G., XUE, R., LIU, M., WANG, F., HU, J., GUO, X. & CHANG, S. 2020. COVID-19 Docking Server: An interactive server for docking small molecules, peptides and antibodies against potential targets of COVID-19. arXiv preprint arXiv:2003.00163.
LASKOWSKI, R. A. & SWINDELLS, M. B. 2011. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model, 51, 2778-86.
LIM, J., JEON, S., SHIN, H.-Y., KIM, M. J., SEONG, Y. M., LEE, W. J., CHOE, K.-W., KANG, Y. M., LEE, B. & PARK, S.-J. 2020. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. Journal of Korean medical science, 35.
LIU, Z., XIAO, X., WEI, X., LI, J., YANG, J., TAN, H., ZHU, J., ZHANG, Q., WU, J. & LIU, L. 2020. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS‐CoV‐2. Journal of medical virology, 92, 595-601.
MOGALIAN, E., GERMAN, P., KEARNEY, B. P., YANG, C. Y., BRAINARD, D., LINK, J., MCNALLY, J., HAN, L., LING, J. & MATHIAS, A. 2017. Preclinical pharmacokinetics and first-in-human pharmacokinetics, safety, and tolerability of velpatasvir, a pangenotypic hepatitis C virus NS5A inhibitor, in healthy subjects. Antimicrobial agents and chemotherapy, 61, e02084-16.
MORRIS, G. M., HUEY, R., LINDSTROM, W., SANNER, M. F., BELEW, R. K., GOODSELL, D. S. & OLSON, A. J. 2009. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem, 30, 2785-91.
O'BOYLE, N. M., BANCK, M., JAMES, C. A., MORLEY, C., VANDERMEERSCH, T. & HUTCHISON, G. R. 2011. Open Babel: An open chemical toolbox. Journal of Cheminformatics, 3, 33.
OMAR, S., BOUZIANE, I., BOUSLAMA, Z. & DJEMEL, A. 2020. In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2.
OMRANI, A. S., SAAD, M. M., BAIG, K., BAHLOUL, A., ABDUL-MATIN, M., ALAIDAROOS, A. Y., ALMAKHLAFI, G. A., ALBARRAK, M. M., MEMISH, Z. A. & ALBARRAK, A. M. 2014. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. The Lancet Infectious Diseases, 14, 1090-1095.
PETTERSEN, E. F., GODDARD, T. D., HUANG, C. C., COUCH, G. S., GREENBLATT, D. M., MENG, E. C. & FERRIN, T. E. 2004. UCSF Chimera—a visualization system for exploratory research and analysis. Journal of computational chemistry, 25, 1605-1612.
TIAN, W., CHEN, C., LEI, X., ZHAO, J. & LIANG, J. 2018. CASTp 3.0: computed atlas of surface topography of proteins. Nucleic Acids Res, 46, W363-w367.
TROTT, O. & OLSON, A. J. 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry, 31, 455-461.
TU, Y.-F., CHIEN, C.-S., YARMISHYN, A. A., LIN, Y.-Y., LUO, Y.-H., LIN, Y.-T., LAI, W.-Y., YANG, D.-M., CHOU, S.-J. & YANG, Y.-P. 2020. A review of SARS-CoV-2 and the ongoing clinical trials. International journal of molecular sciences, 21, 2657.
WANG Z, CHEN X, LU Y, CHEN F & W, Z. 2020. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Bioscience trends, 14 64-68.
WANG, Z., CHEN, X., LU, Y., CHEN, F. & ZHANG, W. 2020. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Bioscience trends, 14, 64-68.
WU, C., LIU, Y., YANG, Y., ZHANG, P., ZHONG, W., WANG, Y., WANG, Q., XU, Y., LI, M. & LI, X. 2020. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B.
ZHANG, H., PENNINGER, J. M., LI, Y., ZHONG, N. & SLUTSKY, A. S. 2020. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive care medicine, 1-5.
ZHU, N., ZHANG, D., WANG, W., LI, X., YANG, B., SONG, J., ZHAO, X., HUANG, B., SHI, W. & LU, R. 2020. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine.
ZOULIM, F., LIANG, T. J., GERBES, A. L., AGHEMO, A., DEUFFIC-BURBAN, S., DUSHEIKO, G., FRIED, M. W., POL, S., ROCKSTROH, J. K. & TERRAULT, N. A. 2015. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut, 64, 1824-1833.